2475 Hanover Street
Palo Alto, California 94304

Biotech investing is at a crossroads. Investors bemoan the FDA, citing endless delays and repeated requests for more information, adding time and cost to the drug development process. Many companies even head to Europe first to launch their drugs, hoping to achieve an exit without dealing with the FDA uncertainty. Despite these problems, biotech investing remains robust. In the latest Money Tree survey, biotech was still the #3 category in dollars invested. Does all this portend continued success for biotech or will the FDA problems lead to a funding reduction? Only our experts know for sure! Come hear our panel discuss these and other issues that are affecting the biotech landscape now and in the future.

8:00am - 8:30am Registration and Breakfast
8:30am - 8:45am Introductions
8:45am - 9:00am Overview
9:00am - 9:45am Panel Discussion
9:45am - 10:00am Q/A, Networking

Confirmed Speakers Include:
Steve Bengston, PricewaterhouseCoopers
Casper de Clercq, Norwest Venture Partners
Jonathan MacQuitty, Abingworth Venture Capital
Eric Shiozaki, Apposite Capital
Moderator: Allison Tilley, Pillsbury Winthrop

Follow us at www.twitter.com/sdforum and tweet with us at #SDFBiotech

Official Website: http://www.sdforum.org/venture-breakfast-series

Added by FullCalendar on June 26, 2011

Interested 1